Vernalis is a development stage pharmaceutical company with one marketed product, frovatriptan, seven product candidates in clinical development and a research capability with significant expertise both in de-novo fragment and structure-based drug discovery.
The individuals who make up the Board and Management team of Vernalis draw on a rich and diverse background of experience from within and outside of the biotech industry.
The Board considers that good corporate governance is an essential element of achieving its overall objectives. Find out more about the Board, as well as the Committees they sit on
To view Vernalis' latest Corporate Profile please follow this link
Product Pipeline
The discovery of novel medicines to treat human disease is the cornerstone of our business. To find out more details of the conditions we are seeking to treat - view our product pipeline.